Adenovirus clinical trials at UCSF
5 in progress, 3 open to eligible people
Adenoviruses are germs that can cause sickness. UCSF is researching how special immune cells might treat stubborn adenovirus infections and studying antibodies in those with heart muscle diseases. Trials are also exploring vaccine combinations to prevent cancer in people with genetic risk factors.
Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
open to eligible people ages 1 month to 79 years
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection…
San Francisco, California and other locations
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
open to eligible people ages 18 years and up
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and …
San Francisco, California and other locations
Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
open to eligible people ages 14-65
This is a multicenter, non-interventional study to observe the natural progression of the disease and to study the prevalence of pre-existing antibodies to AAV9 used for gene therapy in a population of patients with PKP2 gene-associated ARVC.…
San Francisco, California and other locations
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in patients that have a…
San Francisco, California and other locations
rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Sorry, in progress, not accepting new patients
This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a …
San Francisco, California and other locations
Our lead scientists for Adenovirus research studies include Julia Chu, MD Aparajita Singh.
Last updated: